Compare TNDM & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNDM | SDGR |
|---|---|---|
| Founded | 2006 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2013 | 2020 |
| Metric | TNDM | SDGR |
|---|---|---|
| Price | $19.50 | $15.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 9 |
| Target Price | ★ $28.00 | $21.00 |
| AVG Volume (30 Days) | ★ 1.6M | 866.1K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,014,736,000.00 | $255,869,000.00 |
| Revenue This Year | $8.11 | $0.76 |
| Revenue Next Year | $11.85 | $4.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.93 | ★ 23.29 |
| 52 Week Low | $10.00 | $10.95 |
| 52 Week High | $29.65 | $23.02 |
| Indicator | TNDM | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 63.44 | 45.00 |
| Support Level | $17.79 | $14.61 |
| Resistance Level | $20.79 | $16.47 |
| Average True Range (ATR) | 1.04 | 0.59 |
| MACD | 0.28 | -0.11 |
| Stochastic Oscillator | 87.54 | 21.62 |
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.